Krishan Jethwa, GI Radiation Oncologist at Mayo Clinic, shared a post on X:
“CONVERT
LARC with clear MRF
N=663
nCAPOX x 4 vs. nCRT
- LRRFS: 96.3% vs 97.4% (non-inf not established)
- DFS3: 89.2% vs 87.9% (p=NS)
- OS3: 95% vs 94% (p=NS)
Another important study for LARC! This should be viewed in the greater context of: How can we best balance cancer control and long term quality of life/function for our patients – sometimes that is RT omission – sometimes that is organ preservation – sometimes TNT remains ideal.”
Title: Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial
Authors: Wei-Jian Mei, Xiao-Zhong Wang, Xuan Zhang, Yue-Ming Sun, Chun-Kang Yang, Jun-Zhong Lin, Zu-Guang Wu, Rui Zhang, Wei Wang, Yong Li, Ye-Zhong Zhuang, Jian Lei, Xiang-Bin Wan, Ying-Kun Ren, Yong Cheng, Wen-Liang Li, Zi-Qiang Wang, Dong-Bo Xu, Xian-Wei Mo, Hai-Xing Ju, Sheng-Wei Ye, Jing-Lin Zhao, Hong Zhang, Yuan-Hong Gao, Zhi-Fan Zeng, Wei-Wei Xiao, Xiao-Peng Zhang, Yun-Feng Li, E Xie, Yi-Fei Feng, Jing-Hua Tang, Xiao-Jun Wu, Gong Chen, Li-Ren Li, Zhen-Hai Lu, De-Sen Wan, Jin-Xin Bei, Zhi-Zhong Pan, Jie-Hai Yu, Pei-Rong Ding
Read the Full Article.
Other articles featuring Krishan Jethwa on OncoDaily.